Search Results - "Rozalen, Alexandra Zara"

  • Showing 1 - 10 results of 10
Refine Results
  1. 1

    Ductal Adenocarcinoma of the Prostate with Novel Genetic Alterations Characterized by Next-Generation Sequencing by Zara Rozalen, Alexandra, Martin, Jose Manuel, Rajendran, Rithika, Jain, Maneesh, Nava, Victor E

    Published in Current oncology (Toronto) (01-03-2024)
    “…Ductal adenocarcinoma of the prostate (DAP) is an uncommon variant of prostate cancer associated with aggressive disease and poor outcome. It presents most…”
    Get full text
    Journal Article
  2. 2

    Androgen receptor amplification in mesonephric remnants by Siddiqui, Gulnaz, Zara Rozalen, Alexandra, Nava, Victor E

    Published in BMJ case reports (09-06-2023)
    “…Mesonephric remnants (MRs) are embryonic vestiges most commonly found in female pathology specimens from the lateral wall of the cervix. The highly regulated…”
    Get more information
    Journal Article
  3. 3
  4. 4
  5. 5

    Assessing the discordance rate of HER2 expression by immunohistochemistry between primary and secondary prostate cancer biopsies by Mabellos, Joshua, Gill, Puneet, Lap, Coen Johannes Gerardus, Zara Rozalen, Alexandra, Diao, Guoqing, Liu, Shanshan, Thomas, Shrina, Subrahmanyam, Ramesh, Nava, Victor, Jain, Maneesh Rajiv

    Published in Journal of clinical oncology (01-06-2023)
    “…e17014 Background: Preliminary evidence suggests that human epidermal growth factor receptor 2 (HER2) expression may play a role in tumor cell proliferation in…”
    Get full text
    Journal Article
  6. 6

    The prevalence and clinical significance of HER2 overexpression in prostate adenocarcinoma by Estephan, Fayez, Lap, Coen, Jain, Maneesh Rajiv, Nava, Victor, Zara Rozalen, Alexandra, Byrne, Morgan, Diao, Guoqing, Subrahmanyam, Ramesh, Rajendran, Rithika, Martha, Antonio, Banagan, Jeff

    Published in Journal of clinical oncology (20-02-2023)
    “…212 Background: The HER2 oncogene serves as a prognostic marker in breast cancer and is a therapeutic target in breast, lung, and GI malignancies, including…”
    Get full text
    Journal Article
  7. 7

    The prevalence and clinical significance of HER2 expression in prostate adenocarcinoma by Estephan, Fayez, Lap, Coen J, Banagan, Jeff, Antonio, Martha, Liu, Shanshan, Diao, Guoqing, Rozalen, Alexandra Zara, Rajendran, Rithika, Krasnow, Steven, Subrahmanyam, Ramesh, Nava, Victor E, Jain, Maneesh

    Published in Annals of diagnostic pathology (01-12-2023)
    “…Abnormalities in HER2 are well-established oncogenic drivers and are approved therapeutic targets in various malignancies. Prior studies evaluating HER2…”
    Get full text
    Journal Article
  8. 8

    Tumeur atypique multifocale a cellules granuleuses avec altération somatique FLT3 Y842C: Un rapport de cas et revue de la littérature by Zara Rozalen, Alexandra, Garcia, Ruth, Husami, Samir, Marino, Gustavo, Nava, Victor E.

    Published in Tunisie Medicale (01-10-2024)
    “…Introduction: Les tumeurs à cellules granuleuses (TCG) sont des tumeurs principalement bénignes ca- ractérisées par des cellules avec un cytoplasme granulaire…”
    Get full text
    Journal Article
  9. 9

    Atypical Multifocal Granular Cell Tumor with FLT3 Y842C Somatic Mutation: A case report and a review of the literature by Zara Rozalen, Alexandra, Garcia, Ruth, Husami, Samir, Marino, Gustavo, Nava, Victor E

    Published in La Tunisie medicale (05-10-2024)
    “…Granular cell tumors (GCT) are predominantly benign neoplasms composed by cells with abundant eosinophilic granular cytoplasm. Although the majority of GCTs…”
    Get more information
    Journal Article
  10. 10

    Ductal Adenocarcinoma of the Prostate with Novel Genetic Alterations Characterized by Next-Generation Sequencing by Zara Rozalen, Alexandra, Martin, Jose Manuel, Rajendran, Rithika, Jain, Maneesh, Nava, Victor E

    Published in Current oncology (Toronto, Ont.) (19-03-2024)
    “…Ductal adenocarcinoma of the prostate (DAP) is an uncommon variant of prostate cancer associated with aggressive disease and poor outcome. It presents most…”
    Get full text
    Report